Wedoany.com Report on Feb 28th, Mosaic recently announced its full-year 2024 financial results, achieving net earnings of $541 million, with diluted earnings per share of $1.70. Adjusted EBITDA reached $2.4 billion, and adjusted diluted earnings per share were $2.27. These results were primarily driven by the strong performance of the Potash and Mosaic Fertilizantes businesses.

Despite solid full-year performance, Mosaic faced challenges in the fourth quarter, reporting a net loss of $519 million, or a loss per share of $1.64. This loss was mainly impacted by one-time items, including asset impairments and foreign exchange adjustments. Fourth-quarter adjusted EBITDA was $505 million, reflecting weak demand in the U.S. market.

Bruce Bodine, President and CEO of Mosaic, stated, "Mosaic made significant progress in 2025. We strengthened our assets to ensure reliable production, achieved notable cost and efficiency improvements, and divested non-core assets. Delayed demand and rising raw material costs negatively impacted our year-end results, but demand is expected to recover as the planting season approaches."

In terms of business operations, Mosaic's Potash business achieved total production of 8.8 million tonnes in 2025, with potash chloride production reaching its highest level since 2019, setting production records at Esterhazy and Belle Plaine. Mosaic Fertilizantes' operating profit increased by 16% to $277 million, and adjusted EBITDA surged 65% to $567 million.

Phosphate business production in the fourth quarter was 1.7 million tonnes, with continued improvement in early 2026. First-quarter sales are expected to be between 1.7 million and 1.9 million tonnes. Mosaic Biosciences' net sales more than doubled to $68 million in 2025, with a target for further growth in 2026.

Significant pre-tax items in the fourth quarter totaled $422 million, including a $189 million impairment of Carlsbad assets, a $110 million impairment of goodwill and fixed assets at Mosaic Fertilizantes, and $223 million in foreign exchange, market value adjustments, and asset retirement costs. These losses were partially offset by gains from asset sales, such as a $94 million gain from the Patos de Minas transaction.

Selling, general, and administrative expenses for 2025 rose to $534 million, primarily due to the expansion of Mosaic Biosciences, increased employee benefits, and non-cash global digital acceleration costs. Operating cash flow totaled $825 million, down from $1.3 billion in 2024, mainly due to increased working capital and inventory accumulation.

Mosaic also achieved its $150 million value capture target relative to 2023 and plans to add a $100 million target in 2026, demonstrating its ongoing strategy for optimization and growth in core businesses such as Potash and Mosaic Fertilizantes.